Evidence map›Paper›PMID 40083231›Full record

ArticleMolecular oncology2025

Escape from TGF-β-induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells.

Minenur Kalyoncu, Dilara Demirci, Sude Eris, Bengisu Dayanc, Ece Cakiroglu, Merve Basol, Merve Uysal, Gulcin Cakan-Akdogan, Fang Liu, Mehmet Ozturk and 2 more

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Minenur KalyoncuIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0001-8476-6588
Dilara DemirciIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0001-9401-7767
Sude ErisIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0002-2310-8829
Bengisu DayancIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0003-4451-7178
Ece CakirogluIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0002-5761-7760
Merve BasolIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0003-0142-3964
Merve UysalIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0003-0977-0346
Gulcin Cakan-AkdoganIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0002-6356-5979
Fang LiuCenter for Advanced Biotechnology and Medicine, Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.ORCID 0000-0002-3265-4266
Mehmet OzturkDepartment of Medical Biology, Izmir Tinaztepe University School of Medicine, Turkey.ORCID 0000-0002-6092-9706
Gökhan KarakülahIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0001-6706-1375
Serif SenturkIzmir Biomedicine and Genome Center, Turkey.ORCID 0000-0003-3963-2294

Funding

Izmir Biomedicine and Genome CenterScience AcademyTurkish Academy of SciencesTürkiye Bilimsel ve Teknolojik Araştırma Kurumu 217Z168
6 · The paper itself

Abstract

Transforming growth factor-β (TGF-β) signaling and cellular senescence are key hallmarks of hepatocellular carcinoma (HCC) pathogenesis. Despite provoking senescence-associated growth arrest in epithelial HCC cells, elevated TGF-β activity paradoxically correlates with increased aggressiveness and poor prognosis in advanced tumors. Whether the transition between these dichotomous functions involves modulation of the senescence phenotype during disease progression remains elusive. Exploiting the epithelial HCC cell line Huh7 as a robust model, we demonstrate that chronic exposure to TGF-β prompts escape from Smad3-mediated senescence, leading to the development of TGF-β resistance. This altered state is characterized by an optimal proliferation rate and the acquisition of molecular and functional traits of less-differentiated mesenchymal cells, coinciding with differential growth capacity in 2D and 3D culture conditions, epithelial-to-mesenchymal transition (EMT), and increased invasiveness in vitro, and metastasis in vivo. Mechanistically, resistant cells exhibit defective activation and nuclear trafficking of Smad molecules, particularly Smad3, as ectopic activation of the TGF-β/Smad3 axis is able to reinstate TGF-β sensitivity. An integrated transcriptomic landscape reveals both shared and distinct gene signatures associated with senescent and TGF-β resistant states. Importantly, genetic ablation and molecular studies identify microtubule affinity regulating kinase 1 (MARK1) and glutamate metabotropic receptor 8 (GRM8) as critical modulators of the resistance phenomenon, potentially by impairing spatiotemporal signaling dynamics of Smad activity. Our findings unveil a novel phenomenon wherein epithelial HCC cells may exploit senescence plasticity as a mechanism to oppose TGF-β anti-tumor responses and progress towards more aggressive HCC phenotypes.

Indexed as

Carcinoma, HepatocellularCellular SenescenceEpithelial CellsLiver NeoplasmsTransforming Growth Factor betaAnimalsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionHumansMiceSignal TransductionSmad3 ProteinSmad3 ProteinTransforming Growth Factor betaEMThepatocellular carcinomaresistancesenescence escapeTGF‐β

Identifiers

PMID40083231
PMCPMC12420363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.